A five-year-old boy in South Africa provided the first known sample of BA.3.2. On November 22, 2024, a nose swab was taken at a regular surveillance location. When they saw the results, the researchers who sequenced it most likely stopped. Even by the standards of a virus that has accumulated changes over the course of five years, the virus they were examining had more than fifty mutations in its spike protein compared to its parent strain. This level of genetic divergence was uncommon. In terms of evolutionary biology, it appeared to have been somewhere else for a very long time, quietly adapting before making an appearance.
That’s pretty much exactly what took place. The Cicada Covid variant BA.3.2 gets its name from a biological phenomenon that most people learn about in elementary school and quickly forget: the insect that lives underground for years or even decades before suddenly, loudly, and briefly emerging before vanishing once more. Cicada was the name that stuck when Dr. T. Ryan Gregory, an evolutionary biologist at the University of Guelph who has named several noteworthy variants in recent years, started debating names with other variant trackers. It fit. The ancestor strain, BA.3, had briefly coexisted with the initial Omicron wave in late 2021 before disappearing. BA.3 merely vanished from surveillance records, whereas BA.1 and BA.2 caused worldwide surges. It is now thought by scientists that the virus evolved over the years inside a single chronically infected person whose immune system was both active enough to continuously push the virus to change and suppressed enough to prevent it from being eradicated. When BA.3.2 eventually resurfaced, it was a strain with genetic alterations that significantly altered its appearance from anything currently in circulation.
| June 27, 2025 — San Francisco International Airport (traveler from the Netherlands) | Details |
|---|---|
| Variant Name | BA.3.2 (nicknamed “Cicada”) |
| Lineage | Descendant of BA.3, an early Omicron subvariant |
| First Detected | November 22, 2024 — South Africa (5-year-old patient) |
| Estimated Emergence | December 2023 – July 2024 |
| Spike Protein Mutations | 70–75 relative to JN.1 / Wuhan strain; 53 relative to BA.3 |
| Countries Detected | 23+ (as of February 2026) |
| US States (Wastewater) | 29 states + Puerto Rico (as of March 2026) |
| First US Detection | June 27, 2025 — San Francisco International Airport (traveler from Netherlands) |
| WHO Classification | Variant Under Monitoring (December 2025) |
| Severity Assessment | No evidence of increased severe disease or hospitalizations |
| Vaccine Effectiveness | Reduced antibody neutralisation; current vaccines still offer some protection |
| Notable Feature | Appears more prevalent among children; reduced ACE2 binding limits spread |
| Nickname Origin | Named by Dr. T. Ryan Gregory, University of Guelph — after the insect’s long underground dormancy |
| Official Reference | CDC MMWR Report – BA.3.2 Worldwide Surveillance |
The World Health Organization officially designated the cicada COVID variant BA.3.2 as a “Variant Under Monitoring” in December 2025. This designation is one step below “Variant of Interest” and several steps below “Variant of Concern.” This hierarchy is important. It indicates that while scientists are keeping a close eye on the situation, there is currently no reason to be alarmed. Even though it purposefully leaves some questions unanswered, the evidence that is currently available is genuinely comforting in a number of ways. Using data through February 11 of that year, the CDC released a comprehensive surveillance report in March 2026. By then, BA.3.2 had been identified in wastewater samples from 25 US states, detected in 23 countries, and confirmed in clinical specimens from five American patients. That clinical count had increased to 29 patients by the middle of March, spanning 29 states and Puerto Rico, indicating a steady if not rapid growth.
The combination of what BA.3.2 seems to be good at and what it seems to have lost makes it genuinely fascinating to virologists and worthwhile for everyone else to comprehend. In comparison to LP.8.1, the antigen used in the current COVID vaccines for 2025–2026, the variant’s spike protein has 70–75 mutations. Existing antibodies, whether from vaccination or previous infection, are less effective at neutralizing BA.3.2 than they are against the dominant JN.1 descendants, according to laboratory studies. This ability to evade the immune system is real and quantifiable. However, BA.3.2 seems to have less ACE2 binding, which means that its molecular key does not fit into human cells as tightly as those of its rivals. It is believed that this structural trade-off is one of the reasons it has spread globally without causing the kind of sharp infection curves that BA.1 or even JN.1 generated in their initial weeks.
One aspect of the epidemiological data has not gotten as much attention as it should: children seem to be contracting BA.3.2 at a higher rate than adults. Compared to other variants currently in circulation, children are approximately five times more likely to contract this variant, according to an analysis of data from New York City. Scientists interpret this as a reflection of immunity gaps rather than a sign that the virus is more dangerous for children. Younger populations have had less cumulative exposure to the particular Omicron lineages that have been dominant in recent years, so they have less targeted protection against a strain that looks very different from what their immune systems have previously encountered. There is no proof that children have more serious illnesses, and it is important to maintain that distinction.
It’s difficult to ignore the fact that, in comparison to previous variant waves, the public discourse surrounding BA.3.2 is unfolding somewhat differently. There is less fear, in part because the scientists themselves are using remarkably measured language, and in part because people have experienced this cycle enough times to have developed a sort of calibrated fatigue. Dr. Alex Greninger of the University of Washington stated, “It’s not a nothingburger, but it’s like adding grilled onions to your burger.” Although he is careful to note that ongoing monitoring is crucial, Dr. Tulio de Oliveira, whose center in South Africa first discovered the variant, has stated he does not think it warrants inclusion in the next vaccine formulation.
Whether BA.3.2 will eventually accumulate the compensatory mutations required to restore stronger ACE2 binding, which could make it a more aggressive competitor against dominant strains, is still unknown. That is a possibility. It hasn’t occurred. Additionally, some researchers are cautiously optimistic that the variant will continue to be a background presence rather than a headline event because it has had more than a year to make a move without doing so. It is currently being tracked in almost 30 states by the wastewater surveillance systems that found it in Rhode Island weeks before any clinical cases appeared there. This early warning system was nonexistent during the worst stages of the pandemic. That’s at least a reason to be cautiously optimistic about the future.
